Samantha M Ruff1, Reed I Ayabe1, Parisa Malekzadeh1, Meghan L Good1, Michael M Wach1, Melissa K Gonzales2, Amit Tirosh3, Naris Nilubol1, Karel Pacak2, Electron Kebebew4, Dhaval Patel5. 1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland. 3. Neuroendocrine Tumors Service, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel. 4. Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, California. 5. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: divot999@gmail.com.
Abstract
BACKGROUND: Currently, no reliable predictive clinical or laboratory tests exist that can accurately distinguish between benign and malignant pheochromocytomas or paragangliomas (PPGLs). The aim of this study was to investigate if serum microRNA-210 (miR-210) levels could be a marker of malignancy in patients with PPGLs. METHODS: Preoperative serum from patients with PPGLs was collected on the day of surgery. Clinical demographics, germline mutation status, primary tumor size, postoperative biochemical response, and the development of malignant disease were prospectively collected. Total microRNA was extracted from preoperative serum samples, and miR-210 levels were measured by quantitative real-time reverse transcription-polymerase chain reaction and normalized to miR-16. Prognostic variables were compared using univariable and multivariable analyses. RESULTS: Of the 35 patients, 10 (29%) were diagnosed with malignant PPGLs and 25 patients (71%) were diagnosed with benign PPGLs (median follow-up 72.5 mo). Sixty-nine percent of patients had a pheochromocytoma (n = 24/35) compared with 31% of patients with paraganglioma (n = 11/35). The most common germline mutation was succinate dehydrogenase complex subunit B (SDHB) (n = 10). On univariable analysis, lower serum miR-210 expression level (2.3 ± 0.5 versus 3.1 ± 1.2, P = 0.013) and larger primary tumor size (6.7 ± 5.0 cm versus 4.1 ± 2.3 cm, P = 0.043) were significantly associated with malignant disease. No significant prognostic variables were found on multivariable analysis. CONCLUSIONS: In this pilot study, low serum miR-210 expression levels and large primary tumors were identified to be markers of PPGL malignancy on univariable analysis. Given the initial encouraging results in a small cohort, further investigation is warranted to determine if serum miR-210 levels are prognostic.
BACKGROUND: Currently, no reliable predictive clinical or laboratory tests exist that can accurately distinguish between benign and malignant pheochromocytomas or paragangliomas (PPGLs). The aim of this study was to investigate if serum microRNA-210 (miR-210) levels could be a marker of malignancy in patients with PPGLs. METHODS: Preoperative serum from patients with PPGLs was collected on the day of surgery. Clinical demographics, germline mutation status, primary tumor size, postoperative biochemical response, and the development of malignant disease were prospectively collected. Total microRNA was extracted from preoperative serum samples, and miR-210 levels were measured by quantitative real-time reverse transcription-polymerase chain reaction and normalized to miR-16. Prognostic variables were compared using univariable and multivariable analyses. RESULTS: Of the 35 patients, 10 (29%) were diagnosed with malignant PPGLs and 25 patients (71%) were diagnosed with benign PPGLs (median follow-up 72.5 mo). Sixty-nine percent of patients had a pheochromocytoma (n = 24/35) compared with 31% of patients with paraganglioma (n = 11/35). The most common germline mutation was succinate dehydrogenase complex subunit B (SDHB) (n = 10). On univariable analysis, lower serum miR-210 expression level (2.3 ± 0.5 versus 3.1 ± 1.2, P = 0.013) and larger primary tumor size (6.7 ± 5.0 cm versus 4.1 ± 2.3 cm, P = 0.043) were significantly associated with malignant disease. No significant prognostic variables were found on multivariable analysis. CONCLUSIONS: In this pilot study, low serum miR-210 expression levels and large primary tumors were identified to be markers of PPGL malignancy on univariable analysis. Given the initial encouraging results in a small cohort, further investigation is warranted to determine if serum miR-210 levels are prognostic.
Authors: Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer Journal: JAMA Date: 2002-03-20 Impact factor: 56.272
Authors: Goswin Y Meyer-Rochow; Nicole E Jackson; John V Conaglen; Denis E Whittle; Muthusamy Kunnimalaiyaan; Herbert Chen; Gunnar Westin; Johanna Sandgren; Peter Stålberg; Elham Khanafshar; Daniel Shibru; Quan-Yang Duh; Orlo H Clark; Electron Kebebew; Anthony J Gill; Rory Clifton-Bligh; Bruce G Robinson; Diana E Benn; Stan B Sidhu Journal: Endocr Relat Cancer Date: 2010-08-16 Impact factor: 5.678
Authors: Lauren Fishbein; Ignaty Leshchiner; Vonn Walter; Ludmila Danilova; A Gordon Robertson; Amy R Johnson; Tara M Lichtenberg; Bradley A Murray; Hans K Ghayee; Tobias Else; Shiyun Ling; Stuart R Jefferys; Aguirre A de Cubas; Brandon Wenz; Esther Korpershoek; Antonio L Amelio; Liza Makowski; W Kimryn Rathmell; Anne-Paule Gimenez-Roqueplo; Thomas J Giordano; Sylvia L Asa; Arthur S Tischler; Karel Pacak; Katherine L Nathanson; Matthew D Wilkerson Journal: Cancer Cell Date: 2017-02-02 Impact factor: 31.743
Authors: Aguirre A de Cubas; L Javier Leandro-García; Francesca Schiavi; Veronika Mancikova; Iñaki Comino-Méndez; Lucía Inglada-Pérez; Manuel Perez-Martinez; Nuria Ibarz; Pilar Ximénez-Embún; Elena López-Jiménez; Agnieszka Maliszewska; Rocío Letón; Alvaro Gómez Graña; Carmen Bernal; Cristina Alvarez-Escolá; Cristina Rodríguez-Antona; Giuseppe Opocher; Javier Muñoz; Diego Megias; Alberto Cascón; Mercedes Robledo Journal: Endocr Relat Cancer Date: 2013-06-24 Impact factor: 5.678